Înapoi la știri

GPR15-guided CD8+ T regulatory cells control intestinal inflammation - Nature

1 oră în urmă
2 minute min
Elena Dumitrescu
Nature (2026) Cite this article We are providing an unedited version of this manuscript to give early access to its findings. Before final publication, the manuscript will undergo further editing. Please note there may be errors present which affect the content, and all legal disclaimers apply. Inflammatory bowel disease (IBD) causes chronic suffering from gastrointestinal inflammation and dysfunction that can progress to colon cancer1,2. The disease prevalence is increasing and there is an urgent need to better understand its pathogenic mechanisms to improve treatment. We show that GPR15, a G protein-coupled receptor (GPCR) expressed in immune cells and previously described as an entry co-factor for human and simian immunodeficiency viruses3, is a marker and homing receptor for a subset of intramucosal GPR15-guided regulatory CD8+ T lymphocytes (CD8+ TIGR). Deleterious GPR15 gene variants in humans cause defective homing of CD8+ TIGR and are associated with severe early-onset IBD. Moreover, CD8+ TIGR cells are reduced in the intestinal mucosa of sporadic IBD patients. In mice, GPR15 deficiency impairs colonic homing of CD8+ TIGR cells, leading to accumulation of inflammatory macrophages and increased susceptibility to colitis. CD8+ TIGR cells potently kill macrophages activated by intestinal damage or disease using Fas ligand (FasL) and TNF-related weak inducer of apoptosis (TWEAK). The identification of CD8+ TIGR cells yields new insights into organ-specific immune regulation and potential therapeutics for IBD. This is a preview of subscription content, access via your institution Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription Receive 52 print issues and online access Prices may be subject to local taxes which are calculated during checkout
Alte postari din Sanatate
Sanatate

Moderna primește 50 de milioane de dolari pentru a dezvolta un vaccin mARN împotriva Ebola Bundibugyo

În contextul unui focar de Ebola care afectează grav zona, oficialii „întăresc dezvoltarea” vaccinurilor. Potrivit arstechnica.com, Moderna a primit 50 de milioane de dolari pentru a dezvolta un vaccin mARN împotriva virusului Bundibugyo, în timp ce Organizația Mondială a Sănătății (OMS) se implică activ în gestionarea situației.

Acasa Recente Radio Județe